Contact us at 914-666-4665

Dr. Daniel Cameron

Board-certified physician with 38+ years specializing in Lyme disease and tick-borne illnesses. Past President of ILADS (International Lyme and Associated Diseases Society) and first author of ILADS treatment guidelines. Dr. Cameron operates a solo practice focused on patient advocacy and evidence-based Lyme disease treatment. He is the author of 1,100+ articles spanning diagnosis, treatment, co-infections, and recovery from tick-borne illnesses. His work challenges conventional approaches that often leave patients undiagnosed or undertreated, emphasizing clinical judgment over rigid adherence to testing criteria that frequently produce false negatives.

Dr. Daniel Cameron

Treatment guidelines for Lyme disease strike out. An editorial.

There is growing evidence supporting the existence and severity of chronic manifestations of Lyme disease despite recent treatment guidelines for Lyme disease. Studies have found that at least 1 in 3 patients treated for Lyme disease remained ill years after treatment. Furthermore, 4 clinical trials sponsored by the National Institutes of Medicine (NIH) documented the […]

Treatment guidelines for Lyme disease strike out. An editorial. Read More »

Study identifies189 children with Lyme carditis

Heart and Lyme disease complications extend far beyond the classic heart block presentation. A national study identified 189 children with Lyme carditis showing a broad spectrum of cardiac problems — from myocarditis to cardiac arrest — with median treatment costs exceeding $9,000 per child and rising incidence across the United States. By Dr. Daniel Cameron

Study identifies189 children with Lyme carditis Read More »

Borrelia Miyamotoi Test: C6 Peptide May Indicate Infection

Cross-Reactivity Opens Diagnostic Opportunity The C6 peptide Borrelia miyamotoi test may help identify this tick-borne infection. Koetsveld and colleagues examined C6 reactivity in sera from both mice infected with Borrelia miyamotoi and from 46 patients with PCR-positive Borrelia miyamotoi disease (BMD). Their results support the use of the C6 peptide test used for Lyme disease

Borrelia Miyamotoi Test: C6 Peptide May Indicate Infection Read More »

Treatment of Lyme arthritis with disease-modifying antirheumatic drugs (DMARD)

Antirheumatic drugs (DMARDs) are intended to slow down disease progression. Synthetic DMARDs include methotrexate and sulfasalazine. Biological DMARDs include the tumor necrosis factor alpha (TNFα), blockers infliximab (Remicade®), interleukin 1 blockers anakinra (Kineret®), and monoclonal antibodies against B cells (such as rituximab) and the T cell costimulation blocker abatacept (ORENCIA®). The article addressed the factors

Treatment of Lyme arthritis with disease-modifying antirheumatic drugs (DMARD) Read More »

Could advanced imaging reveal cognitive impairment in the brain of a Lyme disease patients?

Multiple studies indicate that neurotransmitter levels can be “related to measures of behavioral outcomes, such as memory, reaction timing,” writes Oeltzschner in the journal Neurobiology of Aging. “These relationships can be region-specific.” Their results might lead to new insights to the brain of Lyme disease patients. Measuring these levels, he adds, “could be a promising

Could advanced imaging reveal cognitive impairment in the brain of a Lyme disease patients? Read More »

Consequences of antibiotic stewardship for Lyme disease patients. An opinion.

Patients who did not receive antibiotics or who had delayed antibiotic treatment had approximately twice as many hospital admissions than patients who had been prescribed antibiotics as soon as symptoms appeared. This paper offers insight into the risk of antibiotic stewardship for Lyme disease. According to their study, more than 13% of the patients did

Consequences of antibiotic stewardship for Lyme disease patients. An opinion. Read More »

My child has Lyme disease. Parents describe fear and frustration.

In fact, one study found that in Ontario, Canada adolescents ages 15 to 19 comprised the group of patients most frequently hospitalized for Lyme disease.¹ And the number of cases is expected to escalate. “Increasing numbers of Canadians, including children and adolescents, are being infected with Borrelia burgdorferi and contracting Lyme disease,” writes Gaudet and

My child has Lyme disease. Parents describe fear and frustration. Read More »

How many patients do not meet the CDC criteria for Lyme disease?

Kobayashi and colleagues concluded that nearly 3 out of 4 patients referred to the clinic did not have Lyme disease using the CDC criteria for Lyme disease. They did not interview the referring doctor at Johns Hopkins University School of Medicine. Instead, they conducted a chart review. However, to be included in the study, patients

How many patients do not meet the CDC criteria for Lyme disease? Read More »

Hispanic risk of Lyme disease.

In their article, “Knowledge and prevention of tick-borne diseases among Hispanic and non-Hispanic residents of Maryland and Virginia,” Hu and colleagues examined U.S. Lyme disease (LD) surveillance data and found that “Hispanics were more likely to have disseminated LD compared with non-Hispanics.” The paper address the Hispanic risk of Lyme disease. The authors summarized several

Hispanic risk of Lyme disease. Read More »